The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: amiodarone hcl     Quarter: 2016Q3

Total Drug/Injury Combinations: 197     Number of Pages: 10

DRUGNAME PT EventCount
AMIODARONE HCL Drug hypersensitivity 9 view events
AMIODARONE HCL Drug interaction 8 view events
AMIODARONE HCL Hyperthyroidism 6 view events
AMIODARONE HCL Drug ineffective 5 view events
AMIODARONE HCL Dyspnoea 5 view events
AMIODARONE HCL Pulmonary toxicity 5 view events
AMIODARONE HCL Toxicity to various agents 5 view events
AMIODARONE HCL Bradycardia 4 view events
AMIODARONE HCL Interstitial lung disease 4 view events
AMIODARONE HCL INJECTION Hyperthyroidism 4 view events
AMIODARONE HCL Asthenia 3 view events
AMIODARONE HCL Cardiac arrest 3 view events
AMIODARONE HCL Cardiac failure 3 view events
AMIODARONE HCL Cough 3 view events
AMIODARONE HCL Haemorrhage 3 view events
AMIODARONE HCL Hypotension 3 view events
AMIODARONE HCL Malaise 3 view events
AMIODARONE HCL Pulmonary fibrosis 3 view events
AMIODARONE HCL Respiratory failure 3 view events
AMIODARONE HCL (manufacturer unknown) Atrial fibrillation 3 view events

Total Drug/Injury Combinations: 197     Number of Pages: 10

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)